According to reports from Axios cited by TechCrunch, biotech startup Colossal Biosciences is in early talks to raise new capital at a massive valuation of $20 billion to $30 billion. This represents a staggering leap for a company focused on "de-extinction" projects, coming just 16 months after it secured a $10.2 billion valuation in early 2025. Currently, specific details regarding the target funding amount or the lead investors for this round have not been officially disclosed.
Diễn biến chi tiết
Colossal Biosciences, founded five years ago by entrepreneur Ben Lamm and geneticist George Church, is famous for its ambitious projects to bring the woolly mammoth, the dodo bird, and the dire wolf back to nature. According to recent reports, the company has started generating revenue over the past year rather than relying solely on research grants. This is a critical financial milestone, proving that the company's business model is beginning to take solid shape.
Co-founder and CEO Ben Lamm previously shared that the company is targetting three main revenue streams. First is providing conservation technology to governments, with the UAE recently reported to have invested $60 million in the firm. Second is the spin-out of satellite startups. To date, Colossal has successfully spun off three startups: Breaking (plastic degradation), Form Bio (computational biology with $30 million raised), and Astromech (AI-driven predictive biology valued at $2 billion in March).
Phân tích kỹ thuật & Công nghệ
Technologically, Colossal Biosciences relies on breakthroughs in CRISPR gene editing and synthetic biology to reconstruct the genomes of extinct species. The research team extracts genetic material from fossils of species like the dire wolf or woolly mammoth, then sequences and fills the gaps using DNA from their closest living relatives, such as Asian elephants.
Furthermore, one of their highly promising core technologies is artificial womb technology for animals. This system is designed not only to nurture resurrected embryos but is also slated to be spun off into an independent startup next year. CEO Ben Lamm stated that artificial womb technology could find significant real-world applications in treating human infertility, unlocking a multi-billion dollar healthcare market.
Ý kiến chuyên gia & Nhận định
Despite attracting massive interest from Silicon Valley and sovereign wealth funds, Colossal's de-extinction projects continue to face skepticism from the global scientific community. Some conservation biologists argue that dedicating immense resources to resurrecting extinct species is "luxurious and impractical" compared to protecting currently endangered animals.
In response to these criticisms, financial analysts at Axios suggest that Colossal's true value lies not in creating a real-life "Jurassic Park," but rather in the spin-off technologies developed during their research. Breakthroughs in gene editing, AI predictive modeling, and artificial reproductive technologies can all be commercialized independently, bringing immediate practical value to modern medicine and agriculture.
Tác động & Tương lai
Should these funding talks succeed, Colossal Biosciences' position within the deep tech sector will be stronger than ever. The company's rise comes amid a booming global interest in longevity tech, alternative energy, and biotechnology.
In the longer term, if Colossal successfully reintroduces extinct species to their native habitats, the company hopes to generate revenue from selling biodiversity credits—a market mechanism similar to carbon credits. For tech enthusiasts and researchers in Vietnam, Colossal's growth serves as a prime example of turning science fiction concepts into a commercial ecosystem capable of reshaping the global biotechnology landscape.